Northbrook, IL, United States
Northbrook, IL, United States
SEARCH FILTERS
Time filter
Source Type

Americas Gold Nanoparticles Market Information by Type (nanorods, nanoshells , nanocages) by Application (photodynamic therapy, diagnostics, medical imaging), by End-users (Hospitals, Clinics,Dental clinics) - Forecast to 2027Pune, India - April 25, 2017 /MarketersMedia/ — Market Scenario The market for Gold nanoparticles is increasing rapidly due to increasing advancement in nanotechnologies. The factors that influence the growth of Gold nanoparticles market; expanding medical diagnostics industry, increasing growth in advance healthcare technology, high advantages in medicinal imaging applications and many others. Key Players • Cytodiagnostics (Canada), • Goldsol (U.S), • NanoHybrids Corp (Austin), • Nanopartz Inc (U.S), • Nanosphere (Canada), • Nanostellar (U.S), • NanoRods LLC (U.S), • Sigma Aldrich (U.S), Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1129 Segments On the basis of types • Nanorods • Nanoshells • Nanocages On the basis of application • Photodynamic therapy • Diagnostics • Medical imaging and others On the basis of End-users • Medical • Electronics • Catalysis Taste the market data and market information presented through more than 50 market data tables and figures spread in 120 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Americas Gold Nanoparticles Market Research Report - Forecast to 2027" Study Objectives of Gold nanoparticles • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Americas Gold nanoparticles market • To provide insights about factors affecting the market growth • To Analyze the Gold nanoparticles market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Rest of the World (ROW) • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by Application, by End-users and its sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The reports cover analysis Americas North America • US • Canada Latin America The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Related Reports Global Blood Transfusion Diagnostics Market Information by Type (Instruments, Reagents), By Application (Blood Grouping, disease Screening), By End users (Hospital, laboratories, Blood Banks, Plasma Fractionation Facilities) - Forecast to 2027.Know more about this report @ https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. Contact Info:Name: Akash AnandEmail: akash.anand@marketresearchfuture.comOrganization: Market Research FutureAddress: Magarpatta Road, Hadapsar,Phone: 6468459349Source URL: http://marketersmedia.com/americas-gold-nanoparticles-market-key-players-analysis-cytodiagnostics-goldsol-nanohybrids-corp-nanopartz-inc-nanosphere-nanostellar-nanorods-llc/189913For more information, please visit https://www.marketresearchfuture.comSource: MarketersMediaRelease ID: 189913


Quasar PN Polycarbonate Prismatic Skylights revolutionize the high performance daylighting industry by providing the highest visible transmission with 100% diffusion in the industry with all the high impact and fire resistance benefits of polycarbonate. Santa Ana, CA, May 24, 2017 --( When it comes to energy efficiency, its all about the light. The U.S. Department of Energy has documented that there isn't a more cost effective solar energy saving option than utilizing high performance skylights with active daylighting controls in industrial/commercial building applications. Research has shown that maximizing visible light transmission while providing greater than 90% diffusion, produces the most hours annually that a skylight can replace the need for electric lighting at the optimum skylight to floor ratio, determined to be 5% or less. Polycarbonate has long been know as a top performer when it comes to impact and fire resistance. The Quasar PN Polycarbonate Prismatic Nanosphere is CC1, Class A fire rated as well as Factory Mutual rated against Class 4, 2" hail and comes with a 10 year hail proof warranty. By tilizing Quasar PN Polycarbonate Prismatic Nanosphere skylights for your daylighting measures, you don't have to give up building protection to get energy performance. Kingspan Light + Air is the newest division of Kingspan Group from Kingscourt, Ireland, a global provider of energy efficient building systems and known as the worlds largest manufacturer of insulated metal building panels. Kingspan Light + Air North America is the new name for Bristolite Daylighting Systems with over 40 years of producing the broadest line of skylight solutions. Kingspan Light + Air Globally is a 2000 employee, €200 million business focused on energy solutions in daylighting, LED, natural ventilation, and smoke and heat evacuation. For more information, please contact our North American Headquarters located in Santa Ana, California toll free at (800) 854-8618 or visit their website at Santa Ana, CA, May 24, 2017 --( PR.com )-- Kingspan Light + Air (the new name for Bristolite Daylighting Systems) has launched the Quasar PN high performance skylight utilizing the latest advancements in polycarbonate plastic coupled with prismatic glazing technology. Through the use of nanospheres embeded in extruded polycarbonate, coupled with prismatic polycarbonate glazing, Kingspan Light + Air has been able to design the highest visible light transmittance (VT) skylight with 100% diffusion available in the industry. The double glazed skylight utilizing the light capturing Triarch Dome shape has been tested under ASTM D1003 to provide 72% VT with 100% haze which provides better lighting performance even when compared to the competition's acrylic prismatic models.When it comes to energy efficiency, its all about the light. The U.S. Department of Energy has documented that there isn't a more cost effective solar energy saving option than utilizing high performance skylights with active daylighting controls in industrial/commercial building applications. Research has shown that maximizing visible light transmission while providing greater than 90% diffusion, produces the most hours annually that a skylight can replace the need for electric lighting at the optimum skylight to floor ratio, determined to be 5% or less. Polycarbonate has long been know as a top performer when it comes to impact and fire resistance. The Quasar PN Polycarbonate Prismatic Nanosphere is CC1, Class A fire rated as well as Factory Mutual rated against Class 4, 2" hail and comes with a 10 year hail proof warranty. By tilizing Quasar PN Polycarbonate Prismatic Nanosphere skylights for your daylighting measures, you don't have to give up building protection to get energy performance.Kingspan Light + Air is the newest division of Kingspan Group from Kingscourt, Ireland, a global provider of energy efficient building systems and known as the worlds largest manufacturer of insulated metal building panels. Kingspan Light + Air North America is the new name for Bristolite Daylighting Systems with over 40 years of producing the broadest line of skylight solutions. Kingspan Light + Air Globally is a 2000 employee, €200 million business focused on energy solutions in daylighting, LED, natural ventilation, and smoke and heat evacuation. For more information, please contact our North American Headquarters located in Santa Ana, California toll free at (800) 854-8618 or visit their website at www.kingspanlightandair.us Kingspan Light + Air North America Grant Grable 800-854-8618 www.kingspanlightandair.us Grant Grable is the Commercial Director of Kingspan Light + Air North America Click here to view the list of recent Press Releases from Kingspan Light + Air North America


News Article | June 5, 2017
Site: globenewswire.com

VANCOUVER, B.C., June 05, 2017 (GLOBE NEWSWIRE) -- Corazon Gold Corp. (TSX-V:CGW) (“Corazon” or the “Company”) is pleased to announce that it has completed its due diligence on NanoSphere Health Sciences LLC (“NanoSphere”) and has signed a binding Merger Agreement dated May 18th, 2017, to acquire 100% of the issued shares of NanoSphere through the merger of NanoSphere and a wholly-owned subsidiary of Corazon (see also Corazon’s press release dated January 5th 2017, available under the Company’s SEDAR profile at www.sedar.com or the Company’s website at www.corazonau.com). Pursuant to the acquisition, Corazon will issue 40,000,000 common shares upon closing and an additional 19,000,000 shares upon initial commercialization of NanoSphere’s products. All common shares issued to the NanoSphere shareholders will be subject to a 3-year pooling. Corazon also intends to complete a financing of $7,000,000 CAD, for which the terms will be announced in short order. Corazon also commissioned an independent comprehensive valuation report on the fair market value of NanoSphere, which was largely based on the existing cannabis division and did not take into account the prospects of NanoSphere’s technology in three other potential future product lines: NSAID’s (non-steroidal anti-inflammatory drugs), nutraceuticals and animal health products.  Based on the weighting of three methodologies, the valuation report concluded a fair market value for NanoSphere (basically, the cannabis division alone, at an early commercialization stage) of up to $24 million CAD, and that the valuation is reasonable given that NanoSphere has developed a proprietary technology/product in a market that is currently highly commoditized. Corazon is also pleased to announce that it is in the process of submitting a listing statement to the Canadian Stock Exchange (CSE).  This move provides greater flexibility to the company while we are developing our revenue streams and will greatly reduce initial listing and on going public company costs. This move also presents opportunities for rapid expansion nationally and internationally. With strong support from the scientific community, a seasoned executive team and a treasury of over $1,000,000 CAD, Corazon is well positioned to take advantage of this truly revolutionary delivery system. Corazon also announces that it has appointed Bennett Liu as chief financial officer, effective immediately, following the resignation of Bao Huo. The company thanks Mr. Huo for his service to the company in the past. Bennett Liu has acquired experience in the areas of financial reporting, regulatory compliance, treasury, and audit in Canada and is an officer of other Canadian public companies. Mr. Liu holds a Diploma in Accounting from British Columbia Institute of Technology. Within NanoSphere’s cannabis division, the NanoSphere Delivery System™ pioneers standardized precision-metered dosages by intra-oral, intra-nasal and transdermal administration within the medical and recreational markets. The NanoSphere Delivery System™ addresses many issues in the traditional delivery of cannabis products by inhalation and ingestion, such as: Recent pharmacokinetic testing (clinical blood studies) confirmed the quick entrance of THC into the bloodstream, within ten minutes, compared to an hour or more with standard ingested THC. The testing also demonstrated significantly higher blood concentrations, greater bioavailability and longer circulation half-life within the human body compared to ingested THC and oral mucosal sprays. NanoSphere’s technology creates an entirely new product category and user-friendly delivery system within the cannabis industry with the potential to greatly expand the patient and adult use markets. Completion of the transaction is subject to a number of conditions, including but not limited to Exchange acceptance and if applicable, disinterested shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Corazon Gold Corp. should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the transaction and has neither approved nor disapproved the contents of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligation to update any forward looking statements, whether as a result of new information, future events or otherwise.


News Article | June 5, 2017
Site: globenewswire.com

VANCOUVER, B.C., June 05, 2017 (GLOBE NEWSWIRE) -- Corazon Gold Corp. (TSX-V:CGW) (“Corazon” or the “Company”) is pleased to announce that it has completed its due diligence on NanoSphere Health Sciences LLC (“NanoSphere”) and has signed a binding Merger Agreement dated May 18th, 2017, to acquire 100% of the issued shares of NanoSphere through the merger of NanoSphere and a wholly-owned subsidiary of Corazon (see also Corazon’s press release dated January 5th 2017, available under the Company’s SEDAR profile at www.sedar.com or the Company’s website at www.corazonau.com). Pursuant to the acquisition, Corazon will issue 40,000,000 common shares upon closing and an additional 19,000,000 shares upon initial commercialization of NanoSphere’s products. All common shares issued to the NanoSphere shareholders will be subject to a 3-year pooling. Corazon also intends to complete a financing of $7,000,000 CAD, for which the terms will be announced in short order. Corazon also commissioned an independent comprehensive valuation report on the fair market value of NanoSphere, which was largely based on the existing cannabis division and did not take into account the prospects of NanoSphere’s technology in three other potential future product lines: NSAID’s (non-steroidal anti-inflammatory drugs), nutraceuticals and animal health products.  Based on the weighting of three methodologies, the valuation report concluded a fair market value for NanoSphere (basically, the cannabis division alone, at an early commercialization stage) of up to $24 million CAD, and that the valuation is reasonable given that NanoSphere has developed a proprietary technology/product in a market that is currently highly commoditized. Corazon is also pleased to announce that it is in the process of submitting a listing statement to the Canadian Stock Exchange (CSE).  This move provides greater flexibility to the company while we are developing our revenue streams and will greatly reduce initial listing and on going public company costs. This move also presents opportunities for rapid expansion nationally and internationally. With strong support from the scientific community, a seasoned executive team and a treasury of over $1,000,000 CAD, Corazon is well positioned to take advantage of this truly revolutionary delivery system. Corazon also announces that it has appointed Bennett Liu as chief financial officer, effective immediately, following the resignation of Bao Huo. The company thanks Mr. Huo for his service to the company in the past. Bennett Liu has acquired experience in the areas of financial reporting, regulatory compliance, treasury, and audit in Canada and is an officer of other Canadian public companies. Mr. Liu holds a Diploma in Accounting from British Columbia Institute of Technology. Within NanoSphere’s cannabis division, the NanoSphere Delivery System™ pioneers standardized precision-metered dosages by intra-oral, intra-nasal and transdermal administration within the medical and recreational markets. The NanoSphere Delivery System™ addresses many issues in the traditional delivery of cannabis products by inhalation and ingestion, such as: Recent pharmacokinetic testing (clinical blood studies) confirmed the quick entrance of THC into the bloodstream, within ten minutes, compared to an hour or more with standard ingested THC. The testing also demonstrated significantly higher blood concentrations, greater bioavailability and longer circulation half-life within the human body compared to ingested THC and oral mucosal sprays. NanoSphere’s technology creates an entirely new product category and user-friendly delivery system within the cannabis industry with the potential to greatly expand the patient and adult use markets. Completion of the transaction is subject to a number of conditions, including but not limited to Exchange acceptance and if applicable, disinterested shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Corazon Gold Corp. should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the transaction and has neither approved nor disapproved the contents of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligation to update any forward looking statements, whether as a result of new information, future events or otherwise.


News Article | June 5, 2017
Site: globenewswire.com

VANCOUVER, B.C., June 05, 2017 (GLOBE NEWSWIRE) -- Corazon Gold Corp. (TSX-V:CGW) (“Corazon” or the “Company”) is pleased to announce that it has completed its due diligence on NanoSphere Health Sciences LLC (“NanoSphere”) and has signed a binding Merger Agreement dated May 18th, 2017, to acquire 100% of the issued shares of NanoSphere through the merger of NanoSphere and a wholly-owned subsidiary of Corazon (see also Corazon’s press release dated January 5th 2017, available under the Company’s SEDAR profile at www.sedar.com or the Company’s website at www.corazonau.com). Pursuant to the acquisition, Corazon will issue 40,000,000 common shares upon closing and an additional 19,000,000 shares upon initial commercialization of NanoSphere’s products. All common shares issued to the NanoSphere shareholders will be subject to a 3-year pooling. Corazon also intends to complete a financing of $7,000,000 CAD, for which the terms will be announced in short order. Corazon also commissioned an independent comprehensive valuation report on the fair market value of NanoSphere, which was largely based on the existing cannabis division and did not take into account the prospects of NanoSphere’s technology in three other potential future product lines: NSAID’s (non-steroidal anti-inflammatory drugs), nutraceuticals and animal health products.  Based on the weighting of three methodologies, the valuation report concluded a fair market value for NanoSphere (basically, the cannabis division alone, at an early commercialization stage) of up to $24 million CAD, and that the valuation is reasonable given that NanoSphere has developed a proprietary technology/product in a market that is currently highly commoditized. Corazon is also pleased to announce that it is in the process of submitting a listing statement to the Canadian Stock Exchange (CSE).  This move provides greater flexibility to the company while we are developing our revenue streams and will greatly reduce initial listing and on going public company costs. This move also presents opportunities for rapid expansion nationally and internationally. With strong support from the scientific community, a seasoned executive team and a treasury of over $1,000,000 CAD, Corazon is well positioned to take advantage of this truly revolutionary delivery system. Corazon also announces that it has appointed Bennett Liu as chief financial officer, effective immediately, following the resignation of Bao Huo. The company thanks Mr. Huo for his service to the company in the past. Bennett Liu has acquired experience in the areas of financial reporting, regulatory compliance, treasury, and audit in Canada and is an officer of other Canadian public companies. Mr. Liu holds a Diploma in Accounting from British Columbia Institute of Technology. Within NanoSphere’s cannabis division, the NanoSphere Delivery System™ pioneers standardized precision-metered dosages by intra-oral, intra-nasal and transdermal administration within the medical and recreational markets. The NanoSphere Delivery System™ addresses many issues in the traditional delivery of cannabis products by inhalation and ingestion, such as: Recent pharmacokinetic testing (clinical blood studies) confirmed the quick entrance of THC into the bloodstream, within ten minutes, compared to an hour or more with standard ingested THC. The testing also demonstrated significantly higher blood concentrations, greater bioavailability and longer circulation half-life within the human body compared to ingested THC and oral mucosal sprays. NanoSphere’s technology creates an entirely new product category and user-friendly delivery system within the cannabis industry with the potential to greatly expand the patient and adult use markets. Completion of the transaction is subject to a number of conditions, including but not limited to Exchange acceptance and if applicable, disinterested shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Corazon Gold Corp. should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the transaction and has neither approved nor disapproved the contents of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligation to update any forward looking statements, whether as a result of new information, future events or otherwise.


DENVER--(BUSINESS WIRE)--NanoSphere Health Sciences, LLC, developer of the innovative, industry-first, patent-pending NanoSphere Delivery System™ for cannabis and other pharmaceuticals, today announces that it has signed a Binding Merger Agreement with Corazon Gold Corp. (TSX-V: CGW), for 100 percent acquisition of NanoSphere’s issued and outstanding shares. This move is pivotal to NanoSphere’s strategy to expand nationally and internationally, getting in on the ground floor of the Canadian cannabis market following new legislation. While medical marijuana has been legal in Canada since 2001, in April, the government filed an act to amend the Controlled Drugs and Substances Act, with the goal of legalizing adult recreational cannabis use by July 2018. As such, Deloitte estimates the base retail value of the Canadian market alone to be upwards of $8 billion. On top of that, Arcview projects the legal marijuana market in the US will hit $20.6 billion in revenue by 2020. “This alignment represents a significant opportunity to take advantage of the nascent Canadian and burgeoning US cannabis markets.” said Robert Sutton, Chairman, NanoSphere Health Sciences. "Across the board, as more countries and states legalize marijuana for recreational and medical use, we are seeing an increased demand for more precise and efficient cannabis delivery methods to help relieve pain and anxiety. NanoSphere’s technology can provide exactly that, addressing many issues faced with traditional delivery methods (like inhalation and ingestion). We look forward to being able provide new customers with a more sophisticated, safer alternative.” The NanoSphere Delivery SystemTM for cannabis pioneers standardized, precision, microlitered dosages by intra-oral, intra-nasal and transdermal administration. Recent pharmacokinetic testing confirmed the rapid entrance of THC into the blood stream when using NanoSphere products. Onset occurs within ten minutes, compared to an hour or more with standard ingested THC. The testing also demonstrated significantly higher blood concentrations, greater bioavailability and loner circulation half-life within the human body compared to ingested THC and oral mucosal spray. Corazon commissioned an extensive and independent company valuation report of NanoSphere Health Sciences’ patent-pending technologies and intellectual property (IP) based on its current application in the cannabis space. This independent report concluded based on the potential of the company’s technology, the valuation of the NanoSphere cannabis division alone is approximately $24 million CAD. The terms of the acquisition are that Corazon will issue 40,000,000 common shares upon closing and an additional 19,000,000 shares upon initial commercialization of NanoSphere’s products. All common shares issued at a deemed price of $0.50 per common share to existing shareholders of NanoSphere. Corazon also intends to complete a financing of $7,000,000 CAD, for which the terms will be announced in short order. NanoSphere is also pleased to announce that it is in the process of submitting a listing statement to the Canadian Securities Exchange (CSE). This move provides greater flexibility to the company while developing revenue streams and will greatly reduce initial listing and on-going pubic company costs. To learn more about NanoSphere Health Sciences, visit www.nanospherehealth.com. About NanoSphere Health Sciences, LLC Headquartered in Denver, Colorado, NanoSphere Health Sciences is a biotechnology firm specializing in the creation of NanoSphere Delivery System™ platform for the supplement, nutraceutical, over-the-counter medications, pharmaceutical, animal health, cannabis industries and beyond. Its patent-pending NanoSphere Delivery System™ represent one of the most important developments for advancing the non-invasive delivery of biological agents in over 25 years. www.nanospherehealth.com. Press Release Disclaimer: This press release contains projections and other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release, including any statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time.


News Article | June 5, 2017
Site: globenewswire.com

VANCOUVER, B.C., June 05, 2017 (GLOBE NEWSWIRE) -- Corazon Gold Corp. (TSX-V:CGW) (“Corazon” or the “Company”) is pleased to announce that it has completed its due diligence on NanoSphere Health Sciences LLC (“NanoSphere”) and has signed a binding Merger Agreement dated May 18th, 2017, to acquire 100% of the issued shares of NanoSphere through the merger of NanoSphere and a wholly-owned subsidiary of Corazon (see also Corazon’s press release dated January 5th 2017, available under the Company’s SEDAR profile at www.sedar.com or the Company’s website at www.corazonau.com). Pursuant to the acquisition, Corazon will issue 40,000,000 common shares upon closing and an additional 19,000,000 shares upon initial commercialization of NanoSphere’s products. All common shares issued to the NanoSphere shareholders will be subject to a 3-year pooling. Corazon also intends to complete a financing of $7,000,000 CAD, for which the terms will be announced in short order. Corazon also commissioned an independent comprehensive valuation report on the fair market value of NanoSphere, which was largely based on the existing cannabis division and did not take into account the prospects of NanoSphere’s technology in three other potential future product lines: NSAID’s (non-steroidal anti-inflammatory drugs), nutraceuticals and animal health products.  Based on the weighting of three methodologies, the valuation report concluded a fair market value for NanoSphere (basically, the cannabis division alone, at an early commercialization stage) of up to $24 million CAD, and that the valuation is reasonable given that NanoSphere has developed a proprietary technology/product in a market that is currently highly commoditized. Corazon is also pleased to announce that it is in the process of submitting a listing statement to the Canadian Stock Exchange (CSE).  This move provides greater flexibility to the company while we are developing our revenue streams and will greatly reduce initial listing and on going public company costs. This move also presents opportunities for rapid expansion nationally and internationally. With strong support from the scientific community, a seasoned executive team and a treasury of over $1,000,000 CAD, Corazon is well positioned to take advantage of this truly revolutionary delivery system. Corazon also announces that it has appointed Bennett Liu as chief financial officer, effective immediately, following the resignation of Bao Huo. The company thanks Mr. Huo for his service to the company in the past. Bennett Liu has acquired experience in the areas of financial reporting, regulatory compliance, treasury, and audit in Canada and is an officer of other Canadian public companies. Mr. Liu holds a Diploma in Accounting from British Columbia Institute of Technology. Within NanoSphere’s cannabis division, the NanoSphere Delivery System™ pioneers standardized precision-metered dosages by intra-oral, intra-nasal and transdermal administration within the medical and recreational markets. The NanoSphere Delivery System™ addresses many issues in the traditional delivery of cannabis products by inhalation and ingestion, such as: Recent pharmacokinetic testing (clinical blood studies) confirmed the quick entrance of THC into the bloodstream, within ten minutes, compared to an hour or more with standard ingested THC. The testing also demonstrated significantly higher blood concentrations, greater bioavailability and longer circulation half-life within the human body compared to ingested THC and oral mucosal sprays. NanoSphere’s technology creates an entirely new product category and user-friendly delivery system within the cannabis industry with the potential to greatly expand the patient and adult use markets. Completion of the transaction is subject to a number of conditions, including but not limited to Exchange acceptance and if applicable, disinterested shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Corazon Gold Corp. should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the transaction and has neither approved nor disapproved the contents of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligation to update any forward looking statements, whether as a result of new information, future events or otherwise.


Patent
Nanosphere | Date: 2012-12-18

The invention relates to methods for detecting complexes of Tau, Tau variants, including phosphorylated variants, and amyloid containing molecules, as well as autoantibodies to those complexes or components of those complexes, in physiological fluid samples.


This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.


Patent
Nanosphere | Date: 2015-04-22

Disclosed are cartridges and modules that may be utilized in diagnostic systems and methods. The cartridge includes a flexible seal that caps the cartridge. The flexible seal has an opening for a pipette tip, and the flexible seal is configured to create a sealed environment when a pipette tip is positioned in the opening of the flexible seal and when the pipette tip is moved in the X-axis, Y-axis, and Z-axis.

Loading Nanosphere collaborators
Loading Nanosphere collaborators